Home › Research › Long-term cohort studies
The role of plasma inflammatory markers in late-life depression and conversion to dementia: a 3-year follow-up study
Mariia Bocharova, Tom Borza, Leiv Otto Watne, Knut Engedal, John Tiernan O'Brien, Geir Selbæk, Ane‐Victoria Idland, John P. Hodsoll et al.. Molecular Psychiatry, 2025-02-08
Topic: Brain proteins, microglia and lab models
Plain-language summary
Late-life depression (LLD) has been linked to increased likelihood of dementia, although mechanisms responsible for this association remain largely unknown. One feature frequently observed in both LLD and dementia is elevated levels of plasma inflammatory markers. The present study aimed to compare the levels of 12 plasma inflammatory markers between older people with LLD and controls, and to explore whether these markers, along with clinical characteristics, can predict dementia in patients with LLD within 3 years of follow-up. Using multiple linear regression with stepwise adjustment, we compared levels of plasma inflammatory markers (IL-1β, IL-1ra, IL-6, IL-10, IL-17a, IL-18, IL-33, TNFα, CD40L, IFN-γ, CCL-2 and CCL-4) between 136 inpatients with LLD (PRODE cohort) and 103 cognitively healthy non-depressed controls (COGNORM cohort). In the PRODE cohort, follow-up data was available for 139 patients (of them 123 had data on baseline plasma inflammatory markers); 36 (25.9%) developed dementia by Year 3 (n = 31 for those with cytokine data). Using Cox proportional hazards regression, we explored whether inflammatory markers and clinical characteristics of LLD (age of onset, treatment response, number of episodes) predicted progression to dementia during follow-up. Levels of IL-1ra, CCL-2, CCL-4, IFN-γ and IL-17a were significantly higher in LLD patients compared to controls in the majority of models. However, none of the inflammatory markers predicted progression from LLD to dementia in the PRODE cohort. Among clinical features, only poor response to treatment significantly predicted higher risk of progression to dementia.
What this study adds
Evidence grade: Moderate
The record lists 31 participants. Several plasma inflammatory markers were higher in older people with late-life depression than in controls, but among clinical features only poor response to treatment significantly predicted progression to dementia within three years. Reported effect size: 25.9%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bocharova, M., Borza, T., Watne, L. O., Engedal, K., O'Brien, J. T., Selbæk, G., et al. (2025). The role of plasma inflammatory markers in late-life depression and conversion to dementia: a 3-year follow-up study. Molecular Psychiatry. https://doi.org/10.1038/s41380-025-02908-2
Vancouver
Bocharova M, Borza T, Watne LO, Engedal K, O'Brien JT, Selbæk G, et al. The role of plasma inflammatory markers in late-life depression and conversion to dementia: a 3-year follow-up study. Molecular Psychiatry. 2025. doi:10.1038/s41380-025-02908-2. PMID: 39922907.
BibTeX
@article{bocharova2025-39922907,
author = {Bocharova, Mariia and Borza, Tom and Watne, Leiv Otto and Engedal, Knut and O'Brien, John Tiernan and Selbæk, Geir and Idland, Ane‐Victoria and Hodsoll, John P. and others},
title = {{The role of plasma inflammatory markers in late-life depression and conversion to dementia: a 3-year follow-up study}},
journal = {Molecular Psychiatry},
year = {2025},
doi = {10.1038/s41380-025-02908-2},
pmid = {39922907},
url = {https://doi.org/10.1038/s41380-025-02908-2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Late-life depression (LLD) has been linked to increased likelihood of dementia, although mechanisms responsible for this association remain largely unknown.
- Levels of IL-1ra, CCL-2, CCL-4, IFN-γ and IL-17a were significantly higher in LLD patients compared to controls in the majority of models.
- Among clinical features, only poor response to treatment significantly predicted higher risk of progression to dementia.
Why it matters
Several plasma inflammatory markers were higher in older people with late-life depression than in controls, but among clinical features only poor response to treatment significantly predicted progression to dementia within three years. The findings suggest inflammation may be relevant to late-life depression, but they do not show that treating inflammation prevents dementia.
Study details
- Participants31
- Effect size25.9%
- Evidence strengthModerate
How this study scored 58/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Molecular Psychiatry) |
| Journal's citation record | 3 / 4 | Molecular Psychiatry: journal h-index 318 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 31 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 17 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 17 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Dag Aarsland: h-index 141 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Cambridge: institution h-index 1,973 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39922907) |
| Free to read | 2 / 2 | Free to read |
| Total | 58 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41380-025-02908-2
- PubMed: 39922907
- Original source →
- Free full text: Molecular Psychiatry →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Long-term cohort studies from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.